Log in

Allergan Stock Price, News & Analysis (NYSE:AGN)

$173.60
+1.10 (+0.64 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$172.65
Now: $173.60
$174.62
50-Day Range
$159.47
MA: $166.16
$174.09
52-Week Range
$114.27
Now: $173.60
$191.72
Volume2.58 million shs
Average Volume3.32 million shs
Market Capitalization$56.96 billion
P/E Ratio10.40
Dividend Yield1.72%
Beta1.65
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP01849010
Phone862-261-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.79 billion
Cash Flow$37.74 per share
Book Value$193.10 per share

Profitability

Net Income$-5,096,400,000.00

Miscellaneous

Employees16,900
Market Cap$56.96 billion
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.


Allergan (NYSE:AGN) Frequently Asked Questions

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan declared a quarterly dividend on Friday, July 19th. Stockholders of record on Tuesday, August 13th will be paid a dividend of $0.74 per share on Friday, September 13th. This represents a $2.96 annualized dividend and a dividend yield of 1.71%. The ex-dividend date of this dividend is Monday, August 12th. View Allergan's Dividend History.

How will Allergan's stock buyback program work?

Allergan announced that its board has approved a share repurchase program on Tuesday, January 29th 2019, which allows the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 4.1% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's leadership believes its shares are undervalued.

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) announced its earnings results on Tuesday, August, 6th. The company reported $4.38 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $4.34 by $0.04. The company had revenue of $4.09 billion for the quarter, compared to analysts' expectations of $3.93 billion. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The company's quarterly revenue was down .8% on a year-over-year basis. During the same period in the previous year, the company posted $4.42 earnings per share. View Allergan's Earnings History.

When is Allergan's next earnings date?

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Allergan.

What guidance has Allergan issued on next quarter's earnings?

Allergan updated its FY19 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of >$16.55 for the period, compared to the Thomson Reuters consensus estimate of $16.74. The company issued revenue guidance of 15.4-15.6 billion, compared to the consensus revenue estimate of $15.32 billion.

What price target have analysts set for AGN?

21 equities research analysts have issued twelve-month price targets for Allergan's stock. Their forecasts range from $144.95 to $255.00. On average, they anticipate Allergan's stock price to reach $179.15 in the next year. This suggests a possible upside of 3.2% from the stock's current price. View Analyst Price Targets for Allergan.

What is the consensus analysts' recommendation for Allergan?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 15 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

Has Allergan been receiving favorable news coverage?

Media headlines about AGN stock have trended somewhat negative on Saturday, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allergan earned a coverage optimism score of -1.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Allergan.

Are investors shorting Allergan?

Allergan saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 10,330,000 shares, an increase of 8.9% from the August 30th total of 9,490,000 shares. Based on an average daily volume of 3,600,000 shares, the days-to-cover ratio is currently 2.9 days. Currently, 3.2% of the company's shares are short sold. View Allergan's Current Options Chain.

Who are some of Allergan's key competitors?

What other stocks do shareholders of Allergan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Who are Allergan's key executives?

Allergan's management team includes the folowing people:
  • Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 49)
  • Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 51)
  • Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 64)
  • Mr. Matthew M. Walsh, Exec. VP & CFO (Age 52)
  • Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 51)

Who are Allergan's major shareholders?

Allergan's stock is owned by many different of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.54%), Commerzbank Aktiengesellschaft FI (0.09%), Robeco Institutional Asset Management B.V. (0.06%), Metropolis Capital Ltd (0.05%), Confluence Investment Management LLC (0.05%) and CIBC Private Wealth Group LLC (0.03%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

Which major investors are selling Allergan stock?

AGN stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Metropolis Capital Ltd, Envestnet Asset Management Inc., West Coast Financial LLC, Confluence Investment Management LLC, Meeder Asset Management Inc., Farmers & Merchants Investments Inc. and Gateway Investment Advisers LLC. View Insider Buying and Selling for Allergan.

Which major investors are buying Allergan stock?

AGN stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Commerzbank Aktiengesellschaft FI, Alpine Group USVI LLC, Alpine Group USVI LLC, Havens Advisors LLC, State of Alaska Department of Revenue, Cerebellum GP LLC and Cerebellum GP LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

How do I buy shares of Allergan?

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $173.60.

How big of a company is Allergan?

Allergan has a market capitalization of $56.96 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

What is Allergan's official website?

The official website for Allergan is http://www.allergan.com/.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]


MarketBeat Community Rating for Allergan (NYSE AGN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  1,350 (Vote Outperform)
Underperform Votes:  647 (Vote Underperform)
Total Votes:  1,997
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel